Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Structure Therapeutics (NASDAQ:GPCR) from a sell rating to a hold rating in a research report released on Saturday.

A number of other equities research analysts have also recently weighed in on the stock. Citizens Jmp dropped their price target on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. Wolfe Research assumed coverage on shares of Structure Therapeutics in a research report on Thursday, March 26th. They set a “peer perform” rating for the company. The Goldman Sachs Group upgraded shares of Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. William Blair reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Finally, Guggenheim lifted their price target on shares of Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.00.

Structure Therapeutics Trading Down 5.1%

Structure Therapeutics stock opened at $50.75 on Friday. Structure Therapeutics has a 12-month low of $15.80 and a 12-month high of $94.90. The stock has a market cap of $3.60 billion, a P/E ratio of -64.24 and a beta of -1.17. The company has a 50-day moving average price of $58.43 and a 200 day moving average price of $54.63.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). As a group, analysts forecast that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC boosted its stake in shares of Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after purchasing an additional 901 shares during the period. State of Wyoming purchased a new position in shares of Structure Therapeutics in the second quarter valued at approximately $28,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Structure Therapeutics in the fourth quarter valued at approximately $127,000. Finally, Banque Cantonale Vaudoise purchased a new position in Structure Therapeutics in the fourth quarter worth approximately $205,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.